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rash, to $2,728 (78 days) for sleep-related symptoms and $4,434 (41 days) for nau-
sea/vomiting. Mean incremental cost per AE episode ranged from $1,581 (rash),
$2,033 (lipid disorders) to $12,834 (nausea/vomiting) and $22,321 (sleep-related).
CONCLUSIONS: Treatment-associated AEs are now essential considerations with
increased HIV patient longevity. In addition to clinical implications, economic
costs should be considered in NNRTI-containing treatment regimen decisions and
for estimating cost-effectiveness of therapy.
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OBJECTIVES:Drugs used in the treatment of Human Immunodeficiency Virus (HIV)
which form part of Highly Active Anti-retroviral Therapy (HAART) are usually ex-
pensive and may have serious side effects. The objective of this study was to
compare the costs and adverse events of a new therapeutic agent, Rilpivirine, with
an established agent, Efavirenz, used in the treatment of HIV, both of which form
part of HAART among treatment naïve patients.METHODS: Decision tree analysis
was used to compare the direct medical costs of using Rilpivirine versus Efavirenz
in HAART from the societal perspective. Drug costs were obtained from an online
drug information source and Red Book 2008. Base case probabilities of having an
adverse event were obtained from a published clinical trial comparing Rilpivirine
versus Efavirenz (N690). Costs for treating adverse events were obtained from the
Medical Expenditure Panel Survey Database (2008). All costs were converted into
2011 US dollars. Sensitivity analyses were performed to determine the effects of
variations in assumptions regarding drug costs and costs for treating adverse
events on study results. All analyses were conducted using the 2011 TreeAge Pro
Software. RESULTS: The analyses showed that Rilpivirine is the treatment of
choice in the first year of therapy with a net cost of $27,282 per patient for Rilpi-
virine as compared to $28,619 per patient for Efavirenz. These results were robust
to changes in assumptions about costs of adverse events. If the cost of Rilpivirine
was higher than $11,610 or if the cost of Efavirenz was lower than $6,387, Efavirenz
would be the treatment of choice. CONCLUSIONS: From a societal standpoint,
Rilpivirine as part of HAART costs less as compared to Efavirenz. Future studies
should aim at comparing Rilpivirine with other established drugs used in the treat-
ment of HIV.
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OBJECTIVES: To determine the incremental economic burden associated with
Clostridium-difficile associated diarrhea (CDAD) among patient sub-populations at
elevated risk for recurrent CDAD: immunocompromised (IC), prior CDAD, concur-
rent antibiotic use (cABx), renally impaired (RI), inflammatory bowel disease (IBD),
and age  65 years (elderly) patients. METHODS: CDAD cases hospitalized with a
diagnosis of CDAD (ICD-9-CM: 008.45) having 12 months of prior health plan
eligibility and 18 years of age between January 1, 2005 and October 31, 2010 were
identified from the HealthCore Integrated Research Database (HIRDSM). CDAD
cases within each sub-population were matched to hospitalized controls without
CDAD diagnosis based on: age10 years, gender, preceding/in-hospital comorbidi-
ties (cardiovascular, pulmonary, haematopoietic, and musculoskeletal) and use of
antibiotics. Incremental hospital length of stay (LOS) and hospital costs were cal-
culated betweenmatched cases and controls usingmultivariate generalized linear
models using a Gamma distribution. Covariates were determined frompost-match
univariate analysis of baseline characteristics for each sub-population. RESULTS:
Post-match case-to-control ratios ranged from 1:1 to 1:3 for each sub-population
(IC: n3,586 cases; prior CDAD: n933 cases; cABx: n4,429 cases; RI: n5,533
cases; IBD: n1,206 cases; elderly: n10,933 cases). Post-match comparisons of
baseline characteristics indicated no significant (P0.05) difference in targeted
match criteria. Compared to controls in all sub-populations, CDAD cases had sig-
nificantly greater (P0.0001) hospital LOS (mean incremental days [95% C.I.]; IC: 8.4
[7.9-9.0]; prior CDAD: 2.9 [2.4-3.6]; cABx: 7.8 [7.4-8.3]; RI: 17.3 [16.4-18.3]; IBD: 3.3
[2.9-3.7]; elderly: 7.8[7.5-8.1]) and hospital costs (mean incremental USD [95% C.I.];
IC: $31.8K [28.5-35.5]; prior CDAD: 28.0K [19.7-40.0]; cABx: 36.3K [33.3-39.6]; RI:
$115.6K [105.2-127.1]; IBD: $11.2K [9.3-13.4]; elderly: $43.2K [40.9-45.7]).
CONCLUSIONS: This study demonstrates the significant incremental economic
burden associated with CDAD both within the hospital setting and from a payer
perspective. CDAD patients in each sub-population incurred significantly greater
hospital LOS and corresponding hospital costs relative to matched controls.
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OBJECTIVES: Complicated skin and skin structure infection (cSSSI) is a common
and costly condition. Telavancin, a bactericidal lipoglycopeptide antibiotic, was
approved in September 2009 as a once-daily therapy for cSSSI. A retrospective
analysis was conducted using the Premier database to compare hospital resource
utilization and costs of cSSSI patients treated with telavancin or daptomycin.
METHODS: Adults with a hospital admission diagnosis of cSSSI receiving telavan-
cin or daptomycin during 2010 were selected. cSSSI was defined by 2011 IDSA
guidelines using ICD-9-CM codes. Logistic regression predicting treatment choice
and clinical opinion were used to identify thematched variables: age, gender, race,
primary diagnosis of cSSSI, prior MRSA infection, APR SOI score, hospital location
of drug initiation, and obesity. Eighty telavancin admissions were matched to 80
daptomycin admissions. Length of stay (LOS) in the hospital and ICU, and post-
drug LOS were analyzed. Costs were calculated using patient billing data. Unad-
justed regression models with gamma distribution and a log link were utilized.
RESULTS: The mean age was 54 years and 64% were male in both groups. Major
underlying conditions included MRSA infection (35 vs. 23%), sepsis (26 vs. 28%),
diabetes (23 vs. 35%), and/or obesity (16 vs. 16%) (telavancin vs. daptomycin, re-
spectively). Patients receiving telavancin had less LOS (11.9 vs. 14.8 days), post-drug
LOS (7.9 vs. 8.8 days), ICU-LOS (3.2 vs. 4.0 days), total hospital costs ($29,791 vs.
$39,054), and pharmacy costs ($4,918 vs. $8,366). Due to large variance in the data,
however, nonewere statistically significant. Total dosing of study drugswas higher
(4,450 mg vs. 3,061 mg) and daily cost was lower ($283 vs. $367) for telavancin
patients. CONCLUSIONS: For all categories, consistently lower resource utilization
and costs in the telavancin group compared to the daptomycin group were ob-
served, although differences were not statistically significant.
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OBJECTIVES: Staphylococcus aureus is a common cause of nosocomial infections in
acute care hospitals. This study aimed to estimate the clinical and economic im-
pact of S. aureus infections associated with surgical procedures in US hospitals.
METHODS: The analysis used the 2009 US National Inpatient Sample data, repre-
senting a 20% sample of 1050 hospitals from 44 states. The seven surgical sub-
groups examined included vascular, cardiothoracic, general, orthopedic, neurosur-
gical, plastic, and GYN/GU surgeries. S. aureus infection rates, length of stay, total
hospital charges and in-hospital mortality were estimated. Multivariate models
adjusted for sampling weights were used for analyses that control for age, gender,
race, payer source, comorbidities, procedure type, admission type and hospital
characteristics. RESULTS: In total, there were 6,894,989 hospitalizations that in-
volved at least 1 of the 7 surgical subgroups among patients age  18. Surgical S.
aureus infectionwas reported as a discharge diagnosis in 61,783 admissions, or 0.90
per 100 admissions (95% CI, 0.85-0.94). S. aureus infection rates varied largely by
surgical subgroups, ranging from 0.12% in GYN/GU to 5.42% in plastic procedures.
The adjusted excess length of stay associated with S. aureus infection was 9.5 days
compared to procedures with no S. aureus infection, ranging from 4.6 days in or-
thopedic procedures to 12.8 days in general procedures. The excess hospital charge
associated with S. aureus infection was also significant at the adjusted mean of
$67,939 compared to no infection. The inpatients with S. aureus infection had 2.1
(95% CI, 1.9-2.3) times the odds of dying in the hospital than patients without S.
aureus infection. CONCLUSIONS: The total number of inpatient S. aureus infections
and its clinical and economic impact on US hospitals were substantial. Prevention
of S. aureus infections would improve clinical outcomes and benefit hospitals and
society in terms of decreased use of scarce health care resources.
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OBJECTIVES: This study aimed to evaluate the costs and outcomes of hospital-
acquired blood stream infections.METHODS: This case control retrospective study
captured data on inpatients in the private hospital for a period of 2 years. The case
group had patients who had developed hospital acquired blood stream infections
and they were matched with controls on the basis of age, primary diagnosis, and
severity of illness. While all the costs were included, the outcome measures ad-
optedwere discharge status, length of stay andmortality of patients.RESULTS:The
results are based on 30matched patients in each arm.While hypertension was the
chief co-morbidity present in both the arms, upto 37% of the patients had none.
Staphylococci and Acinetobacter bauminii/hemolyticus were found to the most com-
mon pathogens, of the 15 identified responsible for causing hospital-acquired
blood stream infections. Polymixins were the most commonly used antimicrobial,
prescribed to 12 patients, followed by Teicoplanin and Linezolid. The 11/30 & 14/30
patients improved in the case and the control group, respectively. The total LOS
and the ICU LOS was significantly higher in the case group compared to controls.
The crudemortality rate for the casewas 53% against 23% for controls. Themedian
of the total cost of treatmentwas statistically significantly higher for the case group
when compared to the control (p0.001). Drug costs accounted for over 50% of the
total costs of treatment. CONCLUSIONS: These results confirm that hospital-ac-
quired blood stream infections pose an additional burden of the health resources &
significantly affect the mortality.
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OBJECTIVES: To measure costs associated with treatment failure among patients
with moderate or complicated CA-MRSA skin infections. METHODS: This was a
prospective, observational study in 4 primary care clinics within the South Texas
Ambulatory Research Network (STARNet). Health care providers collected clinical
data, wound swabs, and 90-day follow-up information. Patientswere considered to
have moderate or complicated infections if they had a lesion 5 cm in diameter,
diabetes mellitus, or both. Patients experienced treatment failure if any of the
following occurred within 90 days of their initial visit: 1) change in antibiotic ther-
apy; 2) subsequent need for incision and drainage [I&D]; 3) subsequent positive
MRSA culture; or 4) hospital admission. The cost analysis was performed from the
perspective of the health insurance payer. Medical costs were derived using esti-
mates from the Agency for Healthcare Research and Quality. National Average
Drug Acquisition Costs, obtained from the Centers for Medicare and Medicaid Ser-
vices, were used to estimate drug costs. All costs were adjusted to 2011 United
States dollars using national medical-care inflation rates. RESULTS: One-third of
patients with moderate or complicated CA-MRSA infections experienced treat-
ment failure (n11/36, 31%). Of the 11who failed therapy, 91% required a change in
antibiotic regimen at an additional mean cost of $4 per person. Eighty percent of
patients who required a change in antibiotics received trimethoprim-sulfame-
thoxazole as initial antibiotic therapy. Patients frequently required the addition of
either clindamycin (50%) or doxycycline (30%) to their initial antibiotic regimen.
Additional I&D procedures were necessary in 27% of patients at a mean cost of
$2130 per person. Finally, 9% of patients required hospitalization at a mean cost of
$17,590 per person. The overall mean cost of treatment failure was $2184 per pa-
tient. No adverse drug events were reported. CONCLUSIONS: One-third of adult
outpatients with moderate or complicated CA-MRSA skin infections will experi-
ence treatment failure at a mean cost of $2184 per patient.
PIN18
COST OF PNEUMOCOCCAL DISEASES IN MEXICO WITH PATIENTS OLDER THAN
50 YEARS OLD: A MICRO-COSTING APPROACH
Peniche-Otero G1, Echaniz-Aviles G2, Herrera-Rojas J1, Ramírez-Ramírez MA1,
Mercado G3, Galindo-Suárez RM3
1Customized Premium Products S.A. de C.V., Mexico City, Mexico, 2Instituto Nacional de Salud
Pública, Cuernavaca, Morelos, Mexico, 3Pfizer S.A. de C.V., Mexico City, Mexico
OBJECTIVES: Streptococcus pneumoniae is one of the most important etiologic
agents of both, respiratory infections and systemic invasive diseases, with signif-
icative rates of morbidity and mortality in the elderly, which represents an eco-
nomic burden. There are few published studies describing the cost of care for
elderly patientswith pneumococcal disease in LatinAmerica. The goal of this study
is to estimate the directmedical costs of the acute phase of pneumococcal diseases,
it=s complications and sequelae in elderly patients in Mexico, regarding the per-
spective of the Social SecurityMexican Institute (IMSS).METHODS: Resource use in
the treatment of pneumonia, bacteremia, meningitis and acute otitis media (AOM)
was extracted from 112 clinic files of patients 50 years with confirmed diagnosis
of pneumococcal disease, treated at Guadalajara, Monterrey and Mexico City hos-
pitals, using a micro-costing approach (bottom-up strategy). Items included in the
analysiswere: drugs, laboratory tests, outpatient and inpatient care, rehabilitation,
procedures and surgical interventions. Resource use for the treatment of compli-
cations and sequelae were derived trough a Delphi panel (n13, infectologists,
pediatricians and internist physicians, IMSS). Concordance index for the Delphi
panel resultswas estimated. The unit cost ofmedical resourceswas extracted from
institutional source. RESULTS: The estimated direct cost (2011 US) associated to
acute phase of pneumococcal diseases were: AOM $323, outpatient pneumonia
$172, inpatient pneumonia $4,718, bacteremia $7,698, meningitis $10,687. Cost of
complications (such as systemic, respiratory, cardiac, etc.) was: AOM US$671, out-
patient pneumonia US$1,502, inpatient pneumonia US$5,157, bacteremia
US$11,267,meningitis US$8,060. The costs of sequelae (such as cardiac, neurologic,
auditive, etc.) were: AOM US$593, outpatient pneumonia US$18, inpatient pneu-
monia US$1,560, bacteremia US$ 1,573, meningitis US$13,297. CONCLUSIONS: The
high institutional costs associated with pneumococcal disease, as well as its com-
plications and sequelae,merit that decisionmakersmaintain and promote preven-
tion policies for this disease in the elderly.
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OBJECTIVES: To estimate the economic cost of probable viral diarrhea in children
less than 5 years old in a 130,800-chlidren cohort in Colombia. METHODS: A de-
scriptive study of economic costs was made. A database of 2010 attentions of a
Health Insurer was analyzed. It has 1,254,000 affiliates (130,800 children under 5
years), resident in 12 Colombian departments. The cases were identified using
international classification of diseases version 10 (A080, A083, A084, A085, A09X).
The types, quantity and frequency of use of health services weremeasured. Types,
quantity and frequency of use of health services were measured. The prices of
services were extracted from the Colombian official prices. Median (interquartile
range: IQR) of direct cost and average length of stay (LOS) in days were calculated.
The costs were calculated for hospitals by levels of complexity to prices of 2011 and
converted to American dollars. RESULTS: A total of 1456 cases of probable viral
diarrheawere identified in children less than five years old. 184 cases (12.64%)were
outpatient. Of inpatients, 42.9% were low level of complexity (LOS: 4.4), 42.8% were
middle of complexity (LOS: 4.1), and 1.3% were high level of complexity (LOS: 3.4).
0.2% of patients required Intensive Care Unit (LOS: 12.6). The median of cost per
outpatient casewasUSD$82.8 (IQR: 51-483); themedian of cost per inpatient case of
middle level of complexity was USD$94 (IQR: 17.4-296.6); and in high level of com-
plexity was US$130.4 (IQR: 81.6-222.6) and in ICU US$3.341 (IQR: 1862-4821). The
total cost of cases was US$182,000.3. CONCLUSIONS:Most probably viral diarrhea
cases are mild with low average of stay. Despite the introduction of the rotavirus
vaccine in early 2009, probably viral diarrhea in children under 5 years in Colombia
has a significant burden of disease in this cohort.
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OBJECTIVES: . To estimate the economic cost of bacterial pneumonia in children
less than 5 years old in a 130,800-chlidren cohort in Colombia. METHODS: . A
descriptive study of economic costs was made. A database of 2010 attentions of a
Health Insurer was analyzed. It has 1,254,000 affiliates (130,800 children under 5
years), resident in 12 Colombian departments. The cases were identified using
international classification of diseases version 10 (J189, J180, J159, J159, J188, J158,
J851, J18, A409, P361, A408). The types, quantity and frequency of use of health
services were measured. Types, quantity and frequency of use of health services
were measured. The prices of services were extracted from the Colombian official
prices. Median (interquartile range: IQR) of direct cost and average length of stay
(LOS) were calculated. The costs were calculated for hospitals by levels of complex-
ity to prices of 2011 and converted to American dollars. RESULTS: . A total of 1545
cases of probable bacterial pneumoniawere identified in children less thanfive years
old (56.7% inunder-2 years). 309 cases (20%)wereoutpatient.Of inpatients, 15.9%were
low level of complexity (LOS: 2.3), 78.1%weremiddle of complexity (LOS: 5.3), and 3.1%
were high level of complexity (LOS: 7.1). 2.9% of patients required Intensive Care Unit
(LOS: 18). The median of cost per outpatient case was USD$98 (IQR: 73–147); The me-
dian of cost per inpatient case of middle level of complexity was USD$254 (IQR: 156-
284); and in high level of complexity was US$488.6 (IQR:135.5-1064.7) and in ICU
US$5,016.5 (IQR:2,568-6,754). The total cost of caseswasUS$871.809.CONCLUSIONS: .
The cases of probable bacterial pneumonia in children under 5 years in Colombia are
a serious public health problem. Most cases are in under-2 years and inpatients of
hospitals of middle level of complexity.
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OBJECTIVES: To examine the economic evidence base, identify gaps in the evi-
dence, and propose potential areas of future enquiry into the economics of rubella,
congenital rubella syndrome (CRS) and rubella vaccination to support the planned
global expansion of rubella-containing vaccine (RCV) and the push towards poten-
tial rubella elimination and eradication. METHODS: A MEDLINE search was con-
ducted of articles published between 1980 and 2010 on costs of rubella and CRS
treatment and the costs, cost-effectiveness or cost-benefit of rubella vaccination.
The design and results of studies were reviewed and categorized by the country
income level. Gaps in the evidence of the costs of rubella and CRS and cost-effec-
tiveness of rubella vaccination and the potential for rubella eradication were
identified. RESULTS: Twenty-five studies were identified. Of the nineteen studies
conducted in high-income countries, 5 were cost analyses, 3 were cost-effective-
ness analyses and 11 were cost-benefit analyses. Of the five studies conducted in
uppermiddle-income countries, fourwere cost analyses and onewas a cost-benefit
study. A single study was conducted in a lower middle-income country and was a
cost-benefit analysis. No studies were conducted in low-income countries. In the
review, CRSwas estimated to cost between $1,994 and $13,482 per case annually or
between $50,000 and $63,990 lifetime in middle-income countries and $98,734 life-
time in high-income countries. The review also found that rubella vaccination
programs had favorable cost-effectiveness, cost-utility, or cost-benefit ratios in
high-income countries and middle-income countries. CONCLUSIONS: Rubella is
costly and rubella vaccination programs are highly cost-effective. However, in or-
der for research to support the drive towards rubella elimination and eradication,
additional studies are required in low-income countries, to tackle methodological
limitations, and determine the most cost-effective strategies for rubella vaccina-
tion.
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OBJECTIVES: Current guidelines for the treatment of acute bacterial skin and skin
structure infections (ABSSSI) recommend aggressive treatment, including hospi-
talization for patients whose infection is progressing despite empiric antibiotic
therapy. In such cases potentially involving S. aureus, guidelines suggest that cli-
nicians should use agents effective againstMRSA because of the high prevalence of
community-associated MRSA strains. This study attempts to ascertain the US eco-
nomic burden and near-term outcomes of in-hospital treatment of ABSSSI during
recent years. METHODS: Using the Premier Hospital Database, hospitalization re-
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